BR112017010132A2 - terapia combinada para tratamento de infecções bacterianas resistentes - Google Patents
terapia combinada para tratamento de infecções bacterianas resistentesInfo
- Publication number
- BR112017010132A2 BR112017010132A2 BR112017010132-7A BR112017010132A BR112017010132A2 BR 112017010132 A2 BR112017010132 A2 BR 112017010132A2 BR 112017010132 A BR112017010132 A BR 112017010132A BR 112017010132 A2 BR112017010132 A2 BR 112017010132A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- bacterial infections
- combination therapy
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- NCCJWSXETVVUHK-ZYSAIPPVSA-N (z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C1C(SCC\N=C/N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21.CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O NCCJWSXETVVUHK-ZYSAIPPVSA-N 0.000 abstract 2
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 abstract 2
- 229960005256 sulbactam Drugs 0.000 abstract 2
- 108090000204 Dipeptidase 1 Proteins 0.000 abstract 1
- 239000003781 beta lactamase inhibitor Substances 0.000 abstract 1
- 102000006635 beta-lactamase Human genes 0.000 abstract 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se a combinações de um inibidor de ß-lactamase com sulbactam e, opcionalmente, imipenem/cilastatina. as combinações são úteis para o tratamento de infecções bacterianas, incluindo infecções causadas por organismos resistentes a fármacos, incluindo patógenos resistentes a múltiplos fármacos. mais particularmente, a invenção refere-se a uma combinação do composto 1 inibidor de ß-lactamase, ou um sal farmaceuticamente aceitável do mesmo, com sulbactam, ou um sal farmaceuticamente aceitável do mesmo e, opcionalmente imipenem/cilastatina ou um sal farmaceuticamente aceitável dos mesmos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080667P | 2014-11-17 | 2014-11-17 | |
| US62/080,667 | 2014-11-17 | ||
| PCT/US2015/061076 WO2016081452A1 (en) | 2014-11-17 | 2015-11-17 | Combination therapy for treatment of resistant bacterial infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017010132A2 true BR112017010132A2 (pt) | 2018-01-02 |
| BR112017010132B1 BR112017010132B1 (pt) | 2023-02-14 |
Family
ID=54704148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017010132-7A BR112017010132B1 (pt) | 2014-11-17 | 2015-11-17 | Combinações e seus usos no tratamento de infecções bacterianas resistentes |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9968593B2 (pt) |
| EP (1) | EP3221313B1 (pt) |
| JP (1) | JP6764862B2 (pt) |
| KR (1) | KR102542392B1 (pt) |
| CN (1) | CN107108624B (pt) |
| AU (1) | AU2015350128B2 (pt) |
| BR (1) | BR112017010132B1 (pt) |
| CA (1) | CA2966632C (pt) |
| CY (1) | CY1121384T1 (pt) |
| DK (1) | DK3221313T3 (pt) |
| EA (1) | EA033829B1 (pt) |
| ES (1) | ES2717776T3 (pt) |
| HK (1) | HK1244798B (pt) |
| HR (1) | HRP20190580T1 (pt) |
| HU (1) | HUE044061T2 (pt) |
| IL (1) | IL251979B (pt) |
| LT (1) | LT3221313T (pt) |
| ME (1) | ME03357B (pt) |
| MX (1) | MX2017006383A (pt) |
| MY (1) | MY196240A (pt) |
| PH (1) | PH12017500852A1 (pt) |
| PL (1) | PL3221313T3 (pt) |
| PT (1) | PT3221313T (pt) |
| RS (1) | RS58429B1 (pt) |
| SG (1) | SG11201703633TA (pt) |
| SI (1) | SI3221313T1 (pt) |
| TR (1) | TR201905233T4 (pt) |
| TW (1) | TWI690317B (pt) |
| WO (1) | WO2016081452A1 (pt) |
| ZA (1) | ZA201703245B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102542392B1 (ko) | 2014-11-17 | 2023-06-09 | 엔타시스 테라퓨틱스 리미티드 | 내성 박테리아 감염의 치료를 위한 배합물 치료제 |
| WO2017203266A1 (en) * | 2016-05-25 | 2017-11-30 | Entasis Therapeutics Limited | Combination therapy for treatment of resistant bacterial infections |
| KR102667828B1 (ko) | 2016-09-16 | 2024-05-20 | 엔타시스 테라퓨틱스 리미티드 | 베타-락타마제 억제제 화합물 |
| EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EA037916B1 (ru) * | 2017-02-08 | 2021-06-07 | Энтасис Терапеутикс Лимитед | Соединения-ингибиторы бета-лактамаз |
| MX2019013291A (es) | 2017-05-08 | 2020-01-15 | Entasis Therapeutics Inc | Compuestos y metodos para tratar infecciones bacterianas. |
| CN109422765B (zh) * | 2017-09-05 | 2020-08-28 | 香港理工大学深圳研究院 | C类β-内酰胺酶抑制剂及其制备方法和应用 |
| PL3765055T3 (pl) * | 2018-03-13 | 2023-11-27 | Sepsia Therapeutics, S.L. | Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| CN111658642A (zh) * | 2019-03-05 | 2020-09-15 | 广州新创忆药物临床研究有限公司 | 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物 |
| TWI715397B (zh) * | 2019-12-31 | 2021-01-01 | 高雄榮民總醫院 | 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體 |
| CN115335054A (zh) * | 2020-04-02 | 2022-11-11 | 葛兰素史克知识产权发展有限公司 | 用吉泊达星治疗淋病奈瑟氏菌的方案 |
| JP2024504342A (ja) * | 2021-01-20 | 2024-01-31 | エンタシス・セラピューティックス・リミテッド | 固定用量抗生物質組成物 |
| WO2023206580A1 (en) * | 2022-04-29 | 2023-11-02 | Entasis Therapeutics Limited | Durlobactam crystalline forms |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU699465B2 (en) | 1993-12-29 | 1998-12-03 | Pfizer Inc. | Diazabicyclic neurokinin antagonists |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) * | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2848210B1 (fr) * | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| FR2914923B1 (fr) | 2007-04-12 | 2013-06-14 | Novexel | Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens. |
| ES2433744T3 (es) * | 2008-01-18 | 2013-12-12 | Merck Sharp & Dohme Corp. | Inhibidores de beta-lactamasas |
| FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
| EP2135959A1 (en) | 2008-06-19 | 2009-12-23 | Novexel | Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| FR2936951B1 (fr) * | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| FR2937034B1 (fr) | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| BR112013032711A2 (pt) | 2011-07-26 | 2017-01-17 | Wockhardt Ltd | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase |
| CA2842779C (en) * | 2011-07-26 | 2016-04-19 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| PT2748165T (pt) | 2011-08-27 | 2016-12-28 | Wockhardt Ltd | Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas |
| EP2872510B1 (en) | 2011-08-30 | 2016-11-23 | Wockhardt Limited | 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections |
| BR112014003476A2 (pt) | 2011-09-13 | 2017-03-01 | Wockhardt Ltd | compostos contendo nitrogênio e seu uso |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| WO2013122888A2 (en) * | 2012-02-15 | 2013-08-22 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| RU2014143821A (ru) | 2012-03-30 | 2016-05-27 | Кьюбист Фармасьютикалз, Инк. | 1, 3, 4-ОКСАДИАЗОЛЬНЫЕ И 1, 3, 4-ТИАДИАЗОЛЬНЫЕ ИНГИБИТОРЫ β-ЛАКТАМАЗЫ |
| US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| SG11201406120SA (en) | 2012-03-30 | 2014-10-30 | Cubist Pharm Inc | ISOXAZOLE β-LACTAMASE INHIBITORS |
| US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| AR090539A1 (es) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| PL2857401T3 (pl) | 2012-05-30 | 2020-02-28 | Meiji Seika Pharma Co., Ltd. | NOWY INHIBITOR ß–LAKTAMAZY I SPOSÓB JEGO WYTWARZANIA |
| BR112015003592B1 (pt) | 2012-08-25 | 2020-04-14 | Wockhardt Ltd | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas |
| CN104768547A (zh) * | 2012-09-03 | 2015-07-08 | 沃克哈特有限公司 | 抗菌组合物 |
| AU2014213795B2 (en) * | 2013-02-06 | 2016-10-13 | Pfizer Anti-Infectives Ab | Combination therapy for the treatment of nosocomial pneumonia |
| WO2014141132A1 (en) * | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
| KR102542392B1 (ko) | 2014-11-17 | 2023-06-09 | 엔타시스 테라퓨틱스 리미티드 | 내성 박테리아 감염의 치료를 위한 배합물 치료제 |
-
2015
- 2015-11-17 KR KR1020177016295A patent/KR102542392B1/ko active IP Right Grant
- 2015-11-17 SI SI201530648T patent/SI3221313T1/sl unknown
- 2015-11-17 RS RS20190328A patent/RS58429B1/sr unknown
- 2015-11-17 CN CN201580062519.5A patent/CN107108624B/zh active Active
- 2015-11-17 CA CA2966632A patent/CA2966632C/en active Active
- 2015-11-17 LT LTEP15801091.8T patent/LT3221313T/lt unknown
- 2015-11-17 PT PT15801091T patent/PT3221313T/pt unknown
- 2015-11-17 ME MEP-2019-80A patent/ME03357B/me unknown
- 2015-11-17 WO PCT/US2015/061076 patent/WO2016081452A1/en active Application Filing
- 2015-11-17 DK DK15801091.8T patent/DK3221313T3/en active
- 2015-11-17 MY MYPI2017000670A patent/MY196240A/en unknown
- 2015-11-17 TW TW104137939A patent/TWI690317B/zh active
- 2015-11-17 PL PL15801091T patent/PL3221313T3/pl unknown
- 2015-11-17 BR BR112017010132-7A patent/BR112017010132B1/pt active IP Right Grant
- 2015-11-17 EP EP15801091.8A patent/EP3221313B1/en active Active
- 2015-11-17 SG SG11201703633TA patent/SG11201703633TA/en unknown
- 2015-11-17 US US15/527,091 patent/US9968593B2/en active Active
- 2015-11-17 HU HUE15801091A patent/HUE044061T2/hu unknown
- 2015-11-17 MX MX2017006383A patent/MX2017006383A/es active IP Right Grant
- 2015-11-17 EA EA201791069A patent/EA033829B1/ru unknown
- 2015-11-17 JP JP2017526516A patent/JP6764862B2/ja active Active
- 2015-11-17 AU AU2015350128A patent/AU2015350128B2/en active Active
- 2015-11-17 ES ES15801091T patent/ES2717776T3/es active Active
- 2015-11-17 TR TR2019/05233T patent/TR201905233T4/tr unknown
-
2017
- 2017-04-27 IL IL251979A patent/IL251979B/en active IP Right Grant
- 2017-05-08 PH PH12017500852A patent/PH12017500852A1/en unknown
- 2017-05-10 ZA ZA2017/03245A patent/ZA201703245B/en unknown
-
2018
- 2018-03-26 HK HK18104155.3A patent/HK1244798B/zh unknown
- 2018-04-09 US US15/947,959 patent/US10376499B2/en active Active
-
2019
- 2019-03-18 CY CY20191100315T patent/CY1121384T1/el unknown
- 2019-03-25 HR HRP20190580TT patent/HRP20190580T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017010132A2 (pt) | terapia combinada para tratamento de infecções bacterianas resistentes | |
| CY1121701T1 (el) | Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων | |
| EA201991523A1 (ru) | Комбинированная терапия амидин-замещенными бета-лактамными соединениями и ингибиторами бета-лактамазы при инфекциях, вызванных бактериальными штаммами, резистентными к антибиотикам | |
| CR20140428A (es) | Compuestos inhibidores de beta-lactamasas | |
| NZ617104A (en) | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| BR112019005053A2 (pt) | compostos inibidores de beta-lactamase | |
| WO2013122888A3 (en) | Methods of treating bacterial infections | |
| BR112015013123A2 (pt) | inibidores de beta-lactamase | |
| MX2017012545A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
| BR112016016853A2 (pt) | Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso | |
| PH12016501988A1 (en) | Antibacterial compounds | |
| MX2017012073A (es) | Compuestos de minociclina para biodefensas. | |
| BR112013008037A2 (pt) | compostos multivalentes como tratamento antibiótico | |
| PH12018502680A1 (en) | Crystal forms of 9-aminomethyl substituted tetracycline compound and preparation method thereof | |
| PH12016501215A1 (en) | Azaindole derivative | |
| BR112017005241A2 (pt) | composto, e, composição farmacêutica. | |
| EA201990738A1 (ru) | Соединения-ингибиторы бета-лактамаз | |
| JO3477B1 (ar) | مركبات أحادي باكتام عضوية لعلاج العدوى البكتيرية | |
| MX2015009505A (es) | Actividad antimicrobiana "in vitro" de la combinacion de peptidos antibiocidas de alacran con antibioticos de uso comun. | |
| BR112017013188A2 (pt) | processo para preparar compostos semelhantes à oxatiazina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: ENTASIS THERAPEUTICS LIMITED (GB) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/11/2015, OBSERVADAS AS CONDICOES LEGAIS |